NCT05985694View on ClinicalTrials.gov

AD17002 Treating Poorly Controlled, Moderate to Severe Eosinophilic Asthma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

November 27, 2023

Primary Completion Date

January 28, 2025

Study Completion Date

April 27, 2025

Conditions
Eosinophilic Asthma
Interventions
DRUG

AD17002

The dosing days of AD17002 are: Days 1, 4, 8, 11, 15, 18, 22, 25, 29, and 32.

DRUG

Placebo

Formulation buffer. Dosing days: 1, 4, 8, 11, 15, 18, 22, 25, 29, 32.

Trial Locations (1)

Unknown

Taipei Medical University Hospital, Taipei

All Listed Sponsors
collaborator

Taipei Medical University Hospital

OTHER

lead

Advagene Biopharma Co. Ltd.

INDUSTRY

NCT05985694 - AD17002 Treating Poorly Controlled, Moderate to Severe Eosinophilic Asthma | Biotech Hunter | Biotech Hunter